Mirum’s Atebrioz Approval Shows Why a Missed Primary Endpoint Does Not Always End a Drug Program

A Regulatory Win With an Unusual Backstory

The FDA approved Atebrioz, or zilurgisertib on September 25 to reduce the volume of total new heterotopic ossification in adults and children aged 12 years and older with fibrodysplasia ossificans progressiva, or FOP.

FOP is an ultra-rare genetic disease caused by mutations in the ACVR1 gene. Muscle, tendons, ligaments and other connective tissues progressively turn into bone, leading to severe loss of mobility and, ultimately, shortened life expectancy.

Atebrioz is a once-daily oral ALK2 inhibitor. The approval gives patients another therapeutic option only about five weeks after FDA approved Regeneron Pharmaceuticals’ Pasatru, an intravenous Activin A-blocking antibody, for adults with FOP.

The timing alone makes this an interesting commercial story.

But the clinical path to approval is arguably more relevant for biotechnology investors.

The pivotal PROGRESS study produced a large treatment effect on new bone formation, but one of the trial’s most prominent prespecified measures did not achieve conventional statistical significance.

Yet the drug was approved.

The Headline Endpoint Did Not Tell the Whole Story

PROGRESS enrolled 63 patients aged 12 years and older and randomized them approximately 1:1 to Atebrioz or placebo for 24 weeks.

One closely watched measure was the proportion of patients developing new heterotopic ossification lesions.

Only 3.1% of Atebrioz-treated patients developed a new lesion compared with 16.7% receiving placebo.

That represented an 81% relative reduction.

The problem was statistical significance.

The result produced a p-value of 0.0986, above the conventional 0.05 threshold.

Look at the trial through another endpoint, however, and the result becomes substantially different.

The volume data showed that patients receiving Atebrioz experienced almost no new heterotopic bone volume, while placebo-treated patients accumulated considerably more.

During the subsequent open-label extension, no new HO lesions were observed through Week 48 among either continuously treated patients or patients who crossed from placebo to Atebrioz.

That changed the regulatory picture.

FDA Focused on Bone Volume, Not Simply Whether a New Lesion Appeared

The final approval language is important.

FDA says Atebrioz’s efficacy was based on the change from baseline in the volume of total new heterotopic ossification, measured using whole-body CT scans.

At Week 24:

• Atebrioz patients had an average 3.2 cm³ decrease in total new HO volume.
• Placebo patients had an average 24.6 cm³ increase.

The difference is substantial.

It also illustrates an important issue in biotechnology investing: whether an endpoint captures the biology of a disease adequately can matter as much as whether a particular statistical test crosses an arbitrary threshold.

A patient developing one extremely small lesion and another developing several large lesions can both be classified simply as having developed a new lesion.

A volume-based endpoint captures substantially more information about the actual amount of abnormal bone formation.

FDA ultimately approved Atebrioz specifically to reduce the volume of total new heterotopic ossification, closely matching the measure on which the clinical effect was clearest.

This Does Not Mean Primary Endpoint Misses No Longer Matter

Investors should be careful not to draw the wrong conclusion.

A failed primary endpoint remains one of the most serious outcomes a biotechnology trial can produce.

FDA does not routinely approve drugs simply because secondary analyses look favorable.

Atebrioz had several characteristics that made its situation unusual:

1. The treatment effect was directionally consistent. The lesion-incidence result missed statistical significance, but the numerical difference strongly favored Atebrioz.
2. The effect on lesion volume was extremely large. New lesion volume was almost completely suppressed relative to placebo.
3. The disease is exceptionally rare and severe. FOP affects roughly one in two million people, and only around 900 patients are diagnosed worldwide.
4. Longer follow-up supported durability. The open-label extension showed no new lesions through Week 48 among treated participants.
5. The endpoint used for approval directly measures the disease process. Heterotopic bone formation is the defining pathology of FOP.

The appropriate investor lesson is therefore not that endpoint misses can be ignored.

It is that the regulatory value of a dataset depends on the magnitude, consistency and clinical relevance of the total evidence, particularly in ultra-rare diseases where conventional large trials may be impossible.

Mirum Acquired the Asset Only Five Months Before Approval

The economics of the transaction are almost as interesting as the regulatory outcome.

Mirum did not develop zilurgisertib internally.

It licensed worldwide rights from Incyte in April 2026, when the NDA was already under FDA review.

The acquisition terms were unusually back-loaded.

Mirum’s June-quarter filing confirms that FDA approval triggers a $25 million milestone payment to Incyte.

That means Mirum secured a now-approved rare-disease asset for $16 million upfront plus the approval milestone and future contingent payments.

For a company with an established rare-disease commercial infrastructure, the transaction offers a useful example of how late-stage licensing can create value differently from internal drug development.

Mirum assumed relatively little clinical-development risk before the U.S. decision.

It now assumes the commercial risk.

Commercialization May Be Harder Than Approval

FOP is an exceptionally small market.

Regeneron estimates that approximately 900 people are diagnosed worldwide, with additional patients likely undiagnosed or misdiagnosed.

Atebrioz will also not enter an empty market.

Three FDA-approved therapies are now available:

The competitive positioning is therefore more complicated than a typical orphan-drug launch.

Atebrioz has the convenience of oral administration, but Sohonos is also oral.

Pasatru requires intravenous administration but generated strong Phase 3 data. In Regeneron’s OPTIMA trial, the approved therapy reduced the number of new HO lesions by 94% at the 3 mg/kg dose and 90% at 10 mg/kg relative to placebo.

Atebrioz consequently enters a tiny market with multiple approved therapies and different mechanisms of action.

That limits how much investors should value the approval in isolation.

The Approval Is Financially Manageable for Mirum

Unlike many biotechnology companies receiving their first FDA approval, Mirum already has a substantial commercial business.

Second-quarter 2026 global net product sales were $176.2 million, up from $127.8 million a year earlier.

LIVMARLI generated $128.7 million, representing 46% year-over-year growth, while the company’s bile-acid medicines contributed another $47.5 million.

Mirum increased full-year 2026 net product sales guidance to $680 million to $700 million.

Its balance sheet also provides room for the Atebrioz launch.

The $25 million approval payment therefore represents less than 5% of Mirum’s June 30 cash and investment balance.

The company can launch Atebrioz without the financing problem that often follows regulatory success at smaller biotechnology companies.

The Market Is Already Valuing Mirum as a Commercial Biotech

Mirum shares closed at $89.70 on September 25, 2026, giving the company a market capitalization of approximately $5.82 billion.

That is roughly:

• 8.3x the upper end of 2026 product-sales guidance on a market-cap-to-sales basis
• 8.8x the midpoint of guidance
• substantially above the valuation normally associated with a single-asset development-stage biotechnology company

The valuation therefore reflects much more than Atebrioz.

Mirum already has a growing commercial franchise and several additional clinical programs. Investors should consequently view Atebrioz primarily as another layer of revenue optionality rather than the central determinant of the company’s valuation.

One external estimate places potential worldwide peak Atebrioz sales at roughly $150 million, although this is an analyst estimate rather than company guidance.

At that level, Atebrioz would be meaningful but still relatively modest beside Mirum’s existing revenue base.

The More Important Read-Through May Be for Other Biotech Companies

Atebrioz may ultimately be more interesting as a regulatory case study than as a standalone commercial asset.

Biotechnology stocks often react mechanically to whether a clinical trial technically “met” or “missed” its primary endpoint.

That shorthand is useful, but incomplete.

The Atebrioz decision shows why investors also need to ask:

• What was the absolute magnitude of treatment effect?
• Did other measures of the same disease process confirm the signal?
• Was the failed statistical test caused partly by a small sample?
• Is the alternative endpoint clinically meaningful?
• Does the disease make a conventional large pivotal trial impractical?
• Is the treatment effect durable?
• What exactly does the eventual FDA label say the drug does?

Those questions become particularly important in rare diseases, where trial populations can be measured in dozens rather than hundreds or thousands.

The Investor Takeaway

Atebrioz is now the 44th novel drug approved by FDA in 2026, but its path to approval makes it more interesting than the ordinal number suggests.

The pivotal study did not produce a conventionally significant result on the proportion of patients developing new lesions. Viewed only through that statistic, the program could have appeared considerably weaker.

The underlying dataset told a different story.

New bone volume was almost completely suppressed relative to placebo, total HO volume moved in opposite directions between the two groups, and longer follow-up supported the durability of the effect. FDA ultimately wrote the indication around the endpoint where the evidence was strongest.

For Mirum, the regulatory risk has now largely converted into commercial risk.

The company acquired worldwide rights only months before approval for a modest upfront payment, has sufficient liquidity to fund the launch, and can place the drug into an existing rare-disease commercial organization.

But Atebrioz is entering an ultra-small market that now contains three approved therapies. That makes market share, physician preference, reimbursement and competitive positioning more important than the approval itself.

For biotechnology investors more broadly, the larger lesson is straightforward: a trial result cannot always be reduced to “met” or “missed.” The structure of the endpoint, the size and consistency of the treatment effect, the disease setting and the regulator’s interpretation of the complete dataset can materially change the value of the same clinical evidence.